Access to hepatitis C treatment for patients in drug substitution programmes: the fight is far from over

Access to hepatitis C treatment for patients in drug substitution programmes: the fight is far from over

Bibliographic Details
Main Authors:	Francesco Negro, Liudmyla Maistat
Format:	Article
Language:	English
Published:	SMW supporting association (Trägerverein Swiss Medical Weekly SMW) 2017-12-01
Series:	Swiss Medical Weekly
Subjects:	continuum of care Hepatitis C opioid substitution therapy people who inject drugs
Online Access:	https://www.smw.ch/index.php/smw/article/view/2422

Similar Items

Hepatitis C virus micro‐elimination in people who inject drugs: Challenges and chance in Taiwan and worldwide
by: Chi‐Ming Tai, et al.
Published: (2024-02-01)

Clinicosocial profile of people who inject drugs receiving opioid substitution therapy at New Delhi
by: Alagarasan Naveen, et al.
Published: (2023-01-01)

A service provider’s experience providing telehealth services during the COVID-19 pandemic in a community-based opioid substitution clinic in Bangladesh
by: Tanveer Khan Ibne Shafiq, et al.
Published: (2024-01-01)

Psychiatrist-led treatment of hepatitis C (HCV) at an opioid agonist treatment (OAT) clinic in Stockholm - enhancing the HCV treatment care cascade
by: M. Kåberg, et al.
Published: (2022-06-01)

The civil society monitoring of hepatitis C response related to the WHO 2030 elimination goals in 35 European countries
by: M. Maticic, et al.
Published: (2020-11-01)

Report from the International Viral Hepatitis Elimination Meeting (IVHEM), 17–18 November 2017, Amsterdam, the Netherlands: gaps and challenges in the WHO 2030 hepatitis C elimination framework
by: Ste.phanie Popping, et al.
Published: (2018-07-01)

History of medication-assisted treatment and its association with initiating others into injection drug use in San Diego, CA
by: Maria Luisa Mittal, et al.
Published: (2017-10-01)

Accessing hepatitis C direct acting antivirals among people living with hepatitis C: a qualitative study
by: Tony Antoniou, et al.
Published: (2023-06-01)

Integrated care model and point of care diagnostics facilitate Hepatitis C treatment among patients receiving opioid agonist therapy: a retrospective review of medical records
by: Margareeta Häkkinen, et al.
Published: (2022-06-01)

A new collaborative care approach toward hepatitis C elimination in marginalized populations
by: Wei-Wen Su, et al.
Published: (2023-08-01)

Hepatitis C micro-elimination among people on opioid agonist therapy is a low-hanging fruit
by: Philip Bruggmann, et al.
Published: (2020-09-01)

Laying the foundations for hepatitis C elimination: evaluating the development and contribution of community care pathways to diagnostic efforts
by: Emma Robinson, et al.
Published: (2023-01-01)

Willingness to use a supervised injection facility among young adults who use prescription opioids non-medically: a cross-sectional study
by: Benjamin A. Bouvier, et al.
Published: (2017-02-01)

A multimorbidity model for estimating health outcomes from the syndemic of injection drug use and associated infections in the United States
by: John J. Chiosi, et al.
Published: (2023-07-01)

Hepatitis C virus risk among young people who inject drugs
by: Pedro Mateu-Gelabert, et al.
Published: (2022-07-01)

A single site study to investigate the current prevalence of anti‐hepatitis C virus antibody among substance use disorder patients in Hiroshima—Insufficient testing and diagnosis
by: Ariyuki Kagaya, et al.
Published: (2023-12-01)

Improving equity and access to buprenorphine treatment through telemedicine at syringe services programs
by: Barrot H. Lambdin, et al.
Published: (2022-07-01)

Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030
by: Philip Bruggmann, et al.
Published: (2017-11-01)

The Importance of Prisons in Achieving Hepatitis C Elimination: Insights from the Australian Experience
by: Rebecca J. Winter, et al.
Published: (2022-02-01)

Factors associated with phylogenetic clustering of hepatitis C among people who inject drugs in Baltimore
by: Oluwaseun Falade-Nwulia, et al.
Published: (2020-11-01)

A simplified point-of-service model for hepatitis C in people who inject drugs in South Africa
by: Elaine Saayman, et al.
Published: (2023-03-01)

Gaps in Hepatitis B Vaccination Completion and Sero-Protection for People Who Inject Drugs in Hpakant, Myanmar, 2015–2018
by: Nilar Shwe Yee, et al.
Published: (2020-05-01)

‘This is hardcore’: a qualitative study exploring service users’ experiences of Heroin-Assisted Treatment (HAT) in Middlesbrough, England
by: Fleur Riley, et al.
Published: (2023-05-01)

Prevalence of HCV among people who inject drugs in Brussels—a respondent-driven sampling survey
by: Luk Van Baelen, et al.
Published: (2020-02-01)

Implementation opportunities for scaling up methadone maintenance treatment in Kyrgyzstan: Methadone dosage and retention on treatment over two years
by: Roman Ivasiy, et al.
Published: (2022-09-01)

Sex and gender differences in hepatitis C virus risk, prevention, and cascade of care in people who inject drugs: systematic review and meta-analysisResearch in context
by: Anna Levinsson, et al.
Published: (2024-06-01)

A missed opportunity: underutilization of inpatient behavioral health services to reduce injection drug use sequelae in Florida
by: Austin E. Coye, et al.
Published: (2021-05-01)

Hepatitis C reinfection in former and active injecting drug users in Belgium
by: Dana Busschots, et al.
Published: (2021-10-01)

Prevalence of hepatitis C infection among the general population and high-risk groups in the EU/EEA: a systematic review update
by: Ru Han, et al.
Published: (2019-07-01)

Interventions to Improve Uptake of Direct-Acting Antivirals for Hepatitis C Virus in Priority Populations: A Systematic Review
by: David Ortiz-Paredes, et al.
Published: (2022-06-01)

The risk of HIV transmission at each step of the HIV care continuum among people who inject drugs: a modeling study
by: Daniel J. Escudero, et al.
Published: (2017-07-01)

Modeling the Impacts of Prevention and Treatment Interventions on Hepatitis C Among People Who Inject Drugs in China
by: Kailu Fang, et al.
Published: (2023-03-01)

Hepatitis C Virus in people with experience of injection drug use following their displacement to Southern Ukraine before 2020
by: Anna Yakovleva, et al.
Published: (2023-07-01)

Egocentric network characteristics of people who inject drugs in the Chicago metro area and associations with hepatitis C virus and injection risk behavior
by: Mary Ellen Mackesy-Amiti, et al.
Published: (2022-06-01)

Setting foot in private spaces: extending the hepatitis C cascade of care to automatic needle/syringe dispensing machines, a mixed methods study
by: Heidi Coupland, et al.
Published: (2022-05-01)

Barriers to management of opioid withdrawal in hospitals in England: a document analysis of hospital policies on the management of substance dependence
by: Magdalena Harris, et al.
Published: (2022-04-01)

Changes to the national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs between 2013 and 2016: a cross-sectional survey of 34 European countries
by: Mojca Maticic, et al.
Published: (2019-05-01)

Integrated care for methadone maintenance patients with hepatitis C virus infection
by: Chi‐Ming Tai, et al.
Published: (2019-08-01)

Ongoing Gaps in the Hepatitis C Care Cascade during the Direct-Acting Antiviral Era in a Large Retrospective Cohort in Canada: A Population-Based Study
by: Ana Maria Passos-Castilho, et al.
Published: (2024-03-01)

HIV- and hepatitis C-related risk behaviors among people who inject drugs in Uganda: implications for policy and programming
by: Matayo Baluku, et al.
Published: (2019-09-01)